Date Filed | Type | Description |
03/20/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
05/23/2017 |
CT ORDER
| Form CT ORDER - Confidential treatment order |
05/30/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
05/20/2014 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Financial Stateme... |
04/17/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
03/20/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
03/18/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
02/20/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
02/14/2014 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2014 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 0% stake in SAVIENT PHARMACEUTICALS, INC. |
02/11/2014 |
SC 13G/A
| VANGUARD GROUP INC reports a 0% stake in Savient Pharmaceuticals Inc |
02/11/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
01/22/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
01/10/2014 |
8-K
| Resignation/termination of a director |
01/07/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/31/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/20/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/13/2013 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
12/05/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/05/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/21/2013 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
11/14/2013 |
10-Q
| Quarterly Report for the period ended September 30, 2013 |
11/12/2013 |
SC 13G/A
| Palo Alto Investors, LLC reports a 0% stake in Savient Pharmaceuticals, Inc. |
11/06/2013 |
8-K
| Quarterly results |
10/30/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
10/21/2013 |
4
| Constantine Ginger (Director) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/18/2013 |
4
| JAEGER STEPHEN O (Director) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC
Txns:
| Sold 38,061 shares
@ $0.05, valued at
$1.9k
|
|
10/17/2013 |
4
| YACHMETZ PHILIP K (Co-President and CBO) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/17/2013 |
4
| Hamill John (Co-President and CFO) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/17/2013 |
4
| CROWLEY Richard (Co-President and COO) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/17/2013 |
4
| Gionco David (Chief Accounting Officer) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/17/2013 |
4
| Bahrt Kenneth (SVP, Chief Medical Officer) has filed a Form 4 on SAVIENT PHARMACEUTICALS INC |
10/15/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
10/15/2013 |
8-K
| Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direc... |
|